932MO Nivolumab (NIVO) plus platinum-doublet chemotherapy (chemo) versus chemo as neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC): Health-related quality of life (HRQoL) outcomes from CheckMate 816.

Authors :: Felip, E.
Wang, C.
Ciuleanu, T-E.
Saylors, G.
Tanaka, F.
Chen, K-N.
Ito, H.
Girard, N.
Lu, S.
Provencio Pulla, M.
Mitsudomi, T.
Awad, M.
Forde, P.M.
Lawrance, R.
Taylor, F.
Worthy, G.
Blum, S.I.
Vo, L.
Cai, J.L.
Spicer, J.
Source :: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS973-S974. 2p.
Publication Year :: 2022

Subjects :: *NON-small-cell lung carcinoma
*NEOADJUVANT chemotherapy
*QUALITY of life
*NIVOLUMAB
*CANCER chemotherapy

Full Text Access

Tools